Beta 2-Adrenergic Receptor in Circulating Cancer-Associated Cells Predicts for Increases in Stromal Macrophages in Circulation and Patient Survival in Metastatic Breast Cancer.
beta-2 adrenergic receptor
breast cancer
cancer-associated macrophage-like cells
circulating tumor cells
epithelial-to-mesenchymal transition cells
Journal
International journal of molecular sciences
ISSN: 1422-0067
Titre abrégé: Int J Mol Sci
Pays: Switzerland
ID NLM: 101092791
Informations de publication
Date de publication:
30 Jun 2022
30 Jun 2022
Historique:
received:
26
05
2022
revised:
22
06
2022
accepted:
27
06
2022
entrez:
9
7
2022
pubmed:
10
7
2022
medline:
14
7
2022
Statut:
epublish
Résumé
The usage of beta blockers in breast cancer (BC) patients is implicated in the reduction in distant metastases, cancer recurrence, and cancer mortality. Studies suggest that the adrenergic pathway is directly involved in sympathetic-driven hematopoietic activation of pro-tumor microenvironmental proliferation and tumor cell trafficking into the circulation. Cancer-associated macrophage-like cells (CAMLs) are pro-tumor polynucleated monocytic cells of hematopoietic origin emanating from tumors which may aid in circulating tumor cell (CTC) dissemination into the circulation. We examined the linkage between Beta-2 adrenergic receptor (B2AR) signaling in CAMLs and CTCs by establishing expression profiles in a model BC cell line (MDA-MB-231). We compared the model to CAMLs and CTCs found in patents. Although internalization events were observed in patients, differences were found in the expression of B2AR between the tumor cell lines and the CAMLs found in patients. High B2AR expression on patients' CAMLs was correlated with significantly more CAMLs in the circulation (
Identifiants
pubmed: 35806301
pii: ijms23137299
doi: 10.3390/ijms23137299
pmc: PMC9266803
pii:
doi:
Substances chimiques
Biomarkers, Tumor
0
Receptors, Adrenergic, beta-2
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Defense Advanced Research Projects Agency
ID : W911NF-14-C-0098
Références
Cancer Epidemiol Biomarkers Prev. 2016 Jul;25(7):1037-42
pubmed: 27197300
Cytometry A. 2018 Dec;93(12):1246-1250
pubmed: 30369050
Breast Cancer Res. 2022 May 23;24(1):35
pubmed: 35606863
J Transl Med. 2020 Nov 4;18(1):413
pubmed: 33148307
Oncotarget. 2010 Nov;1(7):628-38
pubmed: 21317458
PLoS Biol. 2012 Jul;10(7):e1001363
pubmed: 22815651
Sci Rep. 2016 Sep 20;6:33488
pubmed: 27647345
Biomedicines. 2022 Mar 02;10(3):
pubmed: 35327389
J Cell Sci. 2004 Feb 1;117(Pt 4):593-600
pubmed: 14709719
J Clin Oncol. 2011 Jul 1;29(19):2635-44
pubmed: 21632503
Oncotarget. 2014 Oct 30;5(20):10058-69
pubmed: 25375203
FASEB J. 2016 Mar;30(3):1144-54
pubmed: 26578688
Eur Rev Med Pharmacol Sci. 2015 Apr;19(7):1170-81
pubmed: 25912576
J Allergy Clin Immunol. 2006 Jan;117(1):18-24; quiz 25
pubmed: 16387578
Proc Natl Acad Sci U S A. 2014 Mar 4;111(9):3514-9
pubmed: 24550495
Cancers (Basel). 2021 Sep 28;13(19):
pubmed: 34638341
Clin Cancer Res. 2012 Mar 1;18(5):1201-6
pubmed: 22186256
Oncol Res. 2010;19(1):45-54
pubmed: 21141740
Br J Pharmacol. 2012 May;166(2):721-36
pubmed: 22122228
J Cell Biochem. 2017 Sep;118(9):2484-2501
pubmed: 28106295
J Biol Chem. 1992 Feb 15;267(5):3530-8
pubmed: 1371121
Clin Cancer Res. 2017 Oct 1;23(19):5948-5958
pubmed: 28679765
Mol Pharmacol. 1996 Sep;50(3):692-9
pubmed: 8794912
Kidney Int. 2017 Jul;92(1):14-16
pubmed: 28646990
J Clin Oncol. 2011 Jul 1;29(19):2645-52
pubmed: 21632501
Clin Cancer Res. 2017 Aug 15;23(16):4651-4661
pubmed: 28490464
NPJ Precis Oncol. 2021 Mar 19;5(1):25
pubmed: 33742084
J Mammary Gland Biol Neoplasia. 2017 Mar;22(1):43-57
pubmed: 28074314
Oncol Rep. 2016 Jun;35(6):3135-42
pubmed: 27035124